10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
A week after the US Food and Drug Administration (FDA) refused to review idecabtagene vicleucel (ide-cel; bb2121), the European Medicines Agency (EMA) has accepted a filing for the CAR-T therapy. 23 May 2020
Reversing a previous negative decision, the UK’s reimbursement agency has provided final guidance in favor of immunotherapy Tecentriq (atezolizumab), plus chemo, for triple negative breast cancer. 22 May 2020
UK biotech Tiziana Life Sciences today said it intends to demerge its StemPrintER and SPARE (togetherStemPrintER) genomics-based personalized medicine businesses into a separate company and effect a capital reduction to facilitate the spin-out and listing of StemPrintER as an independent entity. 22 May 2020
US clinical-stage drug developer Synlogic’s shares plummeted 25.5% to %1.81 in pre-market trading Thursday after it revealed that its collaboration with AbbVie for the development of Synthetic Biotic medicines for the potential treatment of inflammatory bowel disease (IBD) had been terminated. 22 May 2020
Roche data from two pivotal Phase III open-label extension studies shows satralizumab was well-tolerated as a monotherapy or in combination with baseline immunosuppressive therapy in neuromyelitis optica spectrum disorder (NMOSD). 22 May 2020
A new partnership between South Korea’s Samsung Biologics and UK-based GlaxoSmithKline will ensure additional capacity for the manufacture and supply of GSK's novel biologics. 22 May 2020
In a move aimed at boosting development of its nanopore sequencing technology, Swiss cancer giant Roche has bought out early-stage sequencing expert Stratos Genomics. 22 May 2020
Contrary to conventional wisdom that says the coronavirus pandemic will generally benefit biopharmaceutical companies, a new Pioneer Institute study finds that many companies will emerge from the pandemic commercially weaker, dealing with delays in new product launches and with fewer resources to invest in research and development. 21 May 2020
An update on AstraZeneca’s COVID-19 vaccine candidate, AZD1222, reveals the firm has secured capacity to make one billion doses, with the first deliveries planned for as early as September 2020. 21 May 2020
US biotech Incyte closed up 3.6% at $98.32 yesterday, after announcing, along with partner German drugmaker MorphoSys, the European Marketing Authorization Application (MAA) for tafasitamab, an anti-CD19 antibody, had been validated. 21 May 2020
The European regulator has accepted a submission from Tokyo’s Astellas Pharma for roxadustat, for the treatment of anemia in adults with chronic kidney disease (CKD). 21 May 2020
Shares of USA-based Inovio Pharmaceuticals gained 22.8% in pre-market trading on Wednesday, and were still up 8.4% at $15.79 by close, after the company released encouraging early data on its coronavirus vaccine candidate. 21 May 2020
Ono Pharmaceutical has launched its Velexbru (tirabrutinib hydrochloride), a Bruton’s tyrosine kinase (BTK) inhibitor, for the treatment of recurrent or refractory primary central nervous system lymphoma in Japan. 21 May 2020
Neuromyelitis optica spectrum disorder (NMOSD) is a rare, but serious autoimmune disease, affecting the central nervous system (CNS). This article discusses current pharmaceutical treatments available for NMOSD and explores what is on the horizon for the management of this rare disease. 20 May 2020
Privately-held Galecto has added some boardroom experience in the shape of Amit Munshi, the chief executive of Arena Pharmaceuticals, and David Shapiro, the former chief medical officer of Intercept Pharmaceuticals. 20 May 2020
While the COVID-19 pandemic has impacted us all in ways that were impossible to predict just a few months ago, it seems that venture capitalists are ploughing away, with a heavy focus on the healthcare sector, as revealed in a report from Optimum Strategic Communications. 20 May 2020
Swiss oncology-focused drug discovery firm ADC Therapeutics yesterday said it has closed its initial public offering (IPO) of 14,082,475 shares of its common shares at a price of $19.00 per share, which included the exercise in full by the underwriters of their option to purchase 1,836,844 additional common shares. 20 May 2020
Genocea Biosciences has announced a material transfer agreement (MTA) and exclusive license option with Japan’s Shionogi to develop a novel Herpes simplex virus (HSV)-2 vaccine using Genocea’s proprietary HSV-2 antigens from the GEN-003 program, which the company discontinued in 2017. 20 May 2020
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Cambridge, USA-based City Therapeutics has announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. 9 October 2024
Zephyrm Bioscience, a Cayman Islands-based biotech, has filed for an initial public offering (IPO) in Hong Kong, seeking to raise additional capital to advance its cell therapy pipeline. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024